The critical impact of respiratory and physical therapists in the management of bronchiectasis is emphasized.
This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the bronchiectasis management team.
While the overseeing physician directs evaluations and treatments, an integrated team approach is critical for optimizing bronchiectasis care. Respiratory therapists play vital roles teaching effective airway clearance techniques and devising regimens fitting patient lifestyles to promote adherence. Nurses also provide airway clearance education and self-management training. Physical therapists contribute through pulmonary rehabilitation for qualifying patients.
Infectious disease input helps guide complex infections like highly resistant organisms or unusual nontuberculous mycobacteria. Underlying disorders like cystic fibrosis or primary ciliary dyskinesia occur occasionally, requiring tailored approaches.
Access to genetic counseling is necessary when primary ciliary dyskinesia is suspected. Ultimately, an experienced coordinator facilitating communications/follow-up and assisting troubleshooting maximizes outpatient care quality. An integrated, multidisciplinary care team is essential for delivering comprehensive, high value bronchiectasis care.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More